Medication info
Gemimet Extended-Release Tablet 50/500 mg

Gemimet Extended-Release Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Gemigliptin Tartrate Sesquihydrate›68.9mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
(LG Chem Ltd.)
Appearance
Orange oval film-coated tablet
Packaging
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle, PTP - 28 tablets/PTP [14 tablets/PTP×2], PTP - 56 tablets/PTP [14 tablets/PTP×4]
Approval status
Active

MFDS item code 201507099 · Approved 2015.10.12 · Insurance code 668902990

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability. This medicine is generally administered with the evening meal, and the dose is increased gradually to reduce gastrointestinal adverse reactions associated with metformin. Take one tablet of this medicine 50/500mg extended-release tablet or 50/1000mg extended-release tablet once daily. Patients taking this medicine 25/500mg extended-release tablet or 25/1000mg extended-release tablet should take 2 tablets together once daily. - For patients not currently receiving metformin treatment who require gemigliptin 50mg, the recommended starting dose of this medicine is one gemigliptin 50mg/metformin 500mg extended-release tablet once daily. The dose is increased gradually to reduce gastrointestinal adverse reactions associated with metformin. - For patients switching from combination therapy with gemigliptin and metformin to this medicine, the dose of this medicine may be started at the doses of gemigliptin and metformin they were previously taking. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. The maximum recommended daily dose is gemigliptin 50mg and extended-release metformin 2000mg. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering drugs. Since any change may cause a change in glycemic control, any changes in treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed.

Ingredients

Manufacturer
(LG Chem Ltd.)

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes when taken in combination with gemigliptin and metformin. It can effectively improve blood sugar levels when combined with dietary and exercise therapy. Therefore, it is a suitable treatment for diabetic patients who require blood sugar management.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability. This medicine is generally administered with the evening meal, and the dose is increased gradually to reduce gastrointestinal adverse reactions associated with metformin. Take one tablet of this medicine 50/500mg extended-release tablet or 50/1000mg extended-release tablet once daily. Patients taking this medicine 25/500mg extended-release tablet or 25/1000mg extended-release tablet should take 2 tablets together once daily. - For patients not currently receiving metformin treatment who require gemigliptin 50mg, the recommended starting dose of this medicine is one gemigliptin 50mg/metformin 500mg extended-release tablet once daily. The dose is increased gradually to reduce gastrointestinal adverse reactions associated with metformin. - For patients switching from combination therapy with gemigliptin and metformin to this medicine, the dose of this medicine may be started at the doses of gemigliptin and metformin they were previously taking. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. The maximum recommended daily dose is gemigliptin 50mg and extended-release metformin 2000mg. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering drugs. Since any change may cause a change in glycemic control, any changes in treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed.

Precautions

This medication is used for diabetes treatment and can rarely cause a severe metabolic complication called lactic acidosis. Lactic acidosis is a condition where lactic acid accumulates excessively in the body, and symptoms such as difficulty breathing, muscle pain, and weakness may appear, so caution is warranted. This medication should not be used in patients with poor kidney function, heart failure, or those in serious conditions such as acute myocardial infarction or sepsis. Additionally, patients receiving iodine contrast agents for radiological examinations should stop taking this medication 48 hours before the exam and only resume after confirming normal kidney function. It is not recommended for pregnant or breastfeeding women, and alcohol consumption should be avoided as it may increase the risk of side effects from this medication. During treatment, regular kidney and liver function tests should be conducted, and particularly elderly patients or those with decreased kidney function should be monitored more closely. This medication may cause hypoglycemia, so careful monitoring of blood glucose changes is necessary when used with insulin or sulfonylureas. Additionally, if symptoms of acute pancreatitis, such as severe abdominal pain, occur, medical attention should be sought immediately. During the use of this medication, rare skin rashes, hives, or severe allergic reactions may occur; if any symptoms arise, the medication should be discontinued immediately and a doctor consulted. For surgeries requiring food and drink restrictions, this medication should be stopped at least 48 hours prior to the procedure and resumed only after confirming normal kidney function after surgery. The tablet shell of this medication may be excreted in the stool, but this is due to the inactive ingredients of the medication and does not require concern. However, if it is repeatedly found in the stool, it is advisable to inform a healthcare professional.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • arthralgia
  • nasopharyngitis
  • bacteriuria
  • upper respiratory tract infection
  • increased serum CPK levels
  • increased serum Amylase levels
  • increased Lipase levels
  • fever
Show 95 more
  • diarrhea
  • urinary tract infection
  • dizziness
  • nausea
  • weakness
  • myalgia
  • hypoglycemia
  • hyperglycemia
  • hyperkalemia
  • back pain
  • headache
  • constipation
  • symptomatic hypoglycemia
  • symptomatic hyperglycemia
  • pharyngitis
  • chronic gastritis
  • cough
  • diabetic nephropathy
  • gastritis
  • gingivitis
  • colon polyps
  • urticaria
  • dyspepsia
  • vesicular pemphigoid
  • pruritus
  • rash
  • acute pancreatitis
  • gastric ulcer
  • gum swelling
  • dental disorders
  • periodontitis
  • polyneuropathy
  • sensory disturbances
  • eye twitching
  • neuralgia
  • spinal stenosis
  • sputum disorders
  • sinusitis
  • chronic obstructive pulmonary disease
  • asthma exacerbation
  • dyspnea
  • rash
  • fungal dermatitis
  • dermatitis
  • seborrheic dermatitis
  • skin disorders
  • hepatitis
  • increased gamma-GT
  • hepatic steatosis
  • electrolyte disturbances
  • skeletal pain
  • osteoporosis
  • osteoarthritis
  • ligament disorders
  • cystitis
  • increased serum creatinine
  • acute renal failure
  • proteinuria
  • neurogenic bladder
  • urethral stricture
  • fatigue
  • chest pain
  • leg pain
  • influenza-like illness
  • weight gain
  • motion sickness
  • unspecified ear disease
  • tinnitus
  • glaucoma
  • allergic conjunctivitis
  • decreased appetite
  • anemia
  • folic acid deficiency
  • iron deficiency anemia
  • angina
  • palpitations
  • arrhythmia
  • exacerbation of hypertension
  • increased blood pressure
  • insomnia
  • soft tissue infection
  • intracranial hemorrhage
  • contusion
  • thyroiditis
  • leukocytosis
  • benign prostatic hyperplasia
  • irregular menstruation
  • laceration
  • abdominal pain
  • gastroesophageal reflux
  • cough
  • rhinitis
  • bronchitis
  • increased ALT
  • increased AST

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius. Proper storage can help maintain the effectiveness of the medication for an extended period.

Appearance and packaging

Appearance

Orange oval film-coated tablet

Package unit

Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle, PTP - 28 tablets/PTP [14 tablets/PTP×2], PTP - 56 tablets/PTP [14 tablets/PTP×4]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.